All Tumors
Challenging traditional standards of cancer care through epigenetic innovation. We are pioneering advanced treatment strategies designed to target the root causes of tumor recurrence and improve patient survival.
A Paradigm Shift in Treatment
Epigenetic therapies offer a promising frontier in solid tumor oncology. While historically utilized as monotherapies with limited impact on end stage survival, recent clinical insights have redefined their role. Today, epigenetic agents are proving to be powerful therapeutic modifiers when combined with standard care.
The Role of Epigenetics in Cancer Care
The cancer epigenome is characterized by global DNA methylation and complex chromatin alterations, including the hypermethylation of specific CpG island promoters.
​
Rather than working in isolation, epigenetic agents such as DNA methyltransferase or histone deacetylase inhibitors, which exert a powerful modifier effect when combined with:
​
-
Chemotherapy
-
Hormonal therapy
-
Other targeted epigenetic agents
​
One of the most significant attributes of epigenetic therapy is its ability to target the root cause of disease, cancer stem cells. By forcing these stem cells into a lower plasticity phase, they commit to specific cell lineages, significantly reducing their capacity to reproduce, re-engage in cell cycles, or cause cancer recurrence
Rethinking Tumor Size vs. Patient Survival
A major paradigm shift in modern cancer research involves challenging the traditional relationship between tumor size and patient survival.
The Old Belief
Larger tumors universally correlate with short survival
The Modern Reality
Tumors can metastasize at much smaller, more compact, and, and hypoxic sizes. Therefore, reducing tumor mass does not automatically guarantee extended survival
This shift directly impacts how we approach advanced stage care. The medical community is increasingly questioning the over reliance on aggressive cytotoxic agents in advanced stages when tumor size reduction does not translate to longevity. Notably, while clinical practice has evolved, the traditional RECIST criteria still define a patient with a shrunk tumor as a "responder," even if the overall survival outcome remains unchanged
The MTET Protocol
To address these clinical gaps, Cancer Research and Life Foundation is actively developing the Modified Molecular Targeted Epigenetic Therapy (MTET) protocol. Preclinical data has demonstrated overwhelming success with the MTET protocol in treating advanced and complex cancer cases.